This webinar will provide an overview of how the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado implemented a preemptive pharmacogenomic screening program via a large-scale research biobank and a robust biocomputing system.
CCPM is a multi-institutional collaboration to link extensive patient data to ‘omics’ information and promote development of optimal prognostic and diagnostic tools for the clinical setting.
The CCPM Biobank is collecting DNA from upwards of 500,000 consenting participants under a CLIA/CAP-compliant model. To date, more than 145,000 patients receiving care in the University of Colorado’s health system have consented to participate, and genetic data generated from Illumina’s Multi-Ethnic Genotyping Array (MEGA) have already been generated on the first 30,000. Exome sequencing of 100,000 patients per year is now underway.
To integrate high-dimensionality data being generated on biospecimens with the data captured in CCPM’s data warehouse, a robust computing resource was established. With this infrastructure in place, CCPM developed a clinical pharmacogenomic initiative, which includes preemptive return of clinical results via CCPM’s research biobank, automated clinical decision support (CDS) tools, and development and implementation of proactive strategies to engage stakeholders.